Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Thousands of genes are involved in the regulation of our day-to-day metabolism and relatively little is understood about their function. One key protein, an ABC Transporter called ABCC5, has recently been predicted to be a susceptibility gene for Type 2 diabetes. In a new study selected as Editor's Choice in Obesity, Associate Professor Heidi de Wet has confirmed ABCC5's role in energy metabolism and identified the mechanism behind its metabolic impact for the first time.

© Shutterstock

A multitude of physiological signals regulates our appetite and metabolism. An empty stomach triggers the “hunger hormone”, Ghrelin, which acts on the brain to stimulate feelings of hunger. When the stomach becomes full, those hunger signals are muted. The arrival of digested food in the small intestine from the stomach engages with hormone-secreting cells known as enteroendocrine cells. These cells are the first point of contact between you and your food: the digested food triggers receptors on these endocrine cells causing them to release hormones into the circulatory system. These hormones have very important downstream effects: they regulate the release of insulin from the pancreas, prompt capillaries to move blood towards the stomach to absorb the food, trigger feelings of satiety in the brain, and interacts with the liver, muscle and fat to enable it to absorb glucose. In essence, “these hormones are spectacularly important because they drive human metabolism in response to food.” explains Professor de Wet.

Read more (Department of Physiology, Anatomy & Genetics website)

Also featured in the Oxford Science Blog (University of Oxford website)

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Regular meat consumption linked with a wide range of common diseases

Research

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.